Analysis of neuromuscular blocking drugs and sugammadex expenses, one year after its introduction into routine clinical practice;Analyse des dépenses de curares et de sugammadex après une année d'utilisation en routine clinique

Annales Francaises d'Anesthesie et de Reanimation

Volumn 30, Issue 10, 2011, Pages 758-759

  Raft, J ^a   Chenot, E D ^a   Longrois, D ^b   Meistelman, C ^a,c  

^a CENTRE ALEXIS VAUTRIN   (France)

^b BICHAT HOSPITAL   (France)

^c CHU NANCY BRABOIS   (France)

Author keywords

Overcost; Sugammadex

Indexed keywords

NEUROMUSCULAR BLOCKING AGENT; SUGAMMADEX;

CLINICAL PRACTICE; DRUG COST; LETTER;

ANESTHESIA, GENERAL; CHOLINESTERASE INHIBITORS; COST-BENEFIT ANALYSIS; DRUG UTILIZATION; GAMMA-CYCLODEXTRINS; HUMANS; NEOSTIGMINE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 80053959072     PISSN: 07507658     EISSN: 17696623     Source Type: Journal    
DOI: 10.1016/j.annfar.2011.06.013     Document Type: Letter

References (4)

1. Plaud B. Le sugammadex: une nouveauté qui s'inscrit dans le cadre de l'amélioration de la sécurité des patients ou un simple gadget ?. Ann Fr Anesth Reanim 2009, 28:S64-S69.
2. Chambers D., Paulden M., Paton F., Heirs M., Duffy S., Hunter J.M., et al. Sugammadex for reversal of neuromuscular block after rapid sequence intubation: a systematic review and economic assessment. Br J Anaesth 2010, 105:568-575.
3. Paton F., Paulden M., Chambers D., Heirs M., Duffy S., Hunter J.M., et al. Sugammadex compared with neostigmine/glycopyrrolate for routine reversal of neuromuscular block: a systematic review and economic evaluation. Br J Anaesth 2010, 105:558-567.
4. Beaussier M., Decorps A., Tilleul P., Megnigbeto A., Balladur P., Lienhart A. Desflurane improves the throughput of patients in the PACU. A cost-effectiveness comparison with isoflurane. Can J Anaesth 2002, 49:339-346.